Pentixapharm Holding AG (ETR:PTP) | Finanzwire

Basculer en Français

9807	Companies
196780	Keywords
127779	Articles
104614	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

BRIEF

published on 02/05/2026 at 08:35, 5 hours 2 minutes ago

Pentixapharm's PENTIXAFOR Shows Promise in Non-Invasive Diagnosis of Primary Aldosteronism

Primary Aldosteronism PentixaFor Phase 2 Data Non-invasive Diagnostic PET/CT Imaging
PRESS RELEASE

published on 02/05/2026 at 08:30, 5 hours 7 minutes ago

Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism
Pentixapharm announces Phase 2 study results supporting PENTIXAFOR as a superior non-invasive PET-diagnostic for Primary Aldosteronism, enhancing patient care in hypertension

Phase 2 Molecular Imaging Pentixapharm Primary Aldosteronism PET-diagnostic
BRIEF

published on 01/07/2026 at 08:05, 29 days 5 hours ago

Pentixapharm Receives FDA Feedback for Hypertension Study

FDA Feedback Hypertension Radiopharmaceuticals Phase 3 Study Pentixapharm
PRESS RELEASE

published on 01/07/2026 at 08:00, 29 days 5 hours ago

Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
Pentixapharm receives FDA feedback for Phase 3 diagnostic study in hypertension, providing clarity on study design and approval pathway. Formal guidance enhances IND submission preparations

FDA Feedback Diagnostic Hypertension Phase 3 Study Pentixapharm
BRIEF

published on 12/03/2025 at 08:05, 2 months 2 days ago

Pentixapharm Prepares for Phase 3 PANDA Study on Hypertension Diagnostic

FDA Feedback Hypertension Phase 3 Study Radiodiagnostic CXCR4 Targeting
PRESS RELEASE

published on 12/03/2025 at 08:00, 2 months 2 days ago

Pentixapharm Advances Regulatory Preparations for Phase 3 PANDA Study with Radiodiagnostic Candidate 68Ga-PentixaFor in Hypertension
Pentixapharm advances regulatory preparations for Phase 3 PANDA study with radiodiagnostic candidate 68Ga-PentixaFor in hypertension. FDA provides feedback on clinical protocol

FDA Feedback Hypertension Pentixapharm Phase 3 PANDA Study 68Ga-PentixaFor
BRIEF

published on 11/12/2025 at 08:05, 2 months 23 days ago

Pentixapharm Reports 9-Month Financial Results for 2025

Revenue Financial Loss Guidance Adjustment Pentixapharm 9-Month Results
PRESS RELEASE

published on 11/12/2025 at 08:00, 2 months 23 days ago

Pentixapharm Publishes 9-Month Figures for 2025
Pentixapharm announces 9-month figures for 2025, reports €12.7 million loss. Adjusted guidance projects approximately €18 million loss for the fiscal year. New financial statements available on website

Financial Statements 2025 Loss 9-month Figures Pentixapharm
BRIEF

published on 11/10/2025 at 08:05, 2 months 25 days ago

Pentixapharm to Release Financial Results for Q3 and Nine Months of 2025

Financial Results Oncology Biotech Radiopharmaceuticals Pentixapharm
PRESS RELEASE

published on 11/10/2025 at 08:00, 2 months 25 days ago

Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday, November 12, 2025
Pentixapharm Holding AG to release Third Quarter and First Nine Months 2025 Financial Results on November 12, 2025. Conference call and webcast to follow

Financial Results Conference Call Berlin Radiopharmaceuticals Pentixapharm

1 2 ... 6

Accesswire

Published on 02/05/2026 at 13:20, 17 minutes ago

Guanajuato Silver Sees Significant Growth in Resources at Valenciana
Published on 02/05/2026 at 13:15, 22 minutes ago

Avino Appoints Linda Broughton to The Board of Directors
Published on 02/05/2026 at 13:00, 37 minutes ago

urban-gro to Implement 1-for-25 Reverse Stock Split
Published on 02/05/2026 at 13:00, 37 minutes ago

Gold Terra Provides Update on Drilling Program Along the Campbell Shear South of the Con Mine, Yellowknife, NWT
Published on 02/05/2026 at 13:00, 37 minutes ago

CoTec Notes Portfolio Company HyProMag USA Advances U.S. Hub-And-Spoke Strategy With Arrival of Inserma HDD Pre-Processing Machines at South Carolina and Nevada Sites

View all ACCESSWIRE

EQS Group

Published on 02/05/2026 at 13:04, 33 minutes ago

EQS-Adhoc: Ascory Bank AG raises earnings forecast for financial year 2025
Published on 02/05/2026 at 12:48, 48 minutes ago

Turkiye Garanti Bankasi A.S.: Announcement regarding forward looking statements on the expectations for the year 2026
Published on 02/05/2026 at 12:45, 52 minutes ago

R.E.A. Holdings plc: Notification of Major Holdings
Published on 02/05/2026 at 11:47, 1 hour 50 minutes ago

Worthington Steel Announces Start of Acceptance Period for All-Cash Tender Offer of €11.00 per Share to Shareholders of Kloeckner & Co SE
Published on 02/05/2026 at 11:46, 1 hour 51 minutes ago

Amundi Physical Metals plc: UK Final Terms

Les Echos

Published on 02/05/2026 at 11:30, 2 hours 7 minutes ago

Disclosure of shares outstanding and voting rights - 05.02.2026
Published on 02/04/2026 at 18:04, 19 hours 33 minutes ago

Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 19 hours 52 minutes ago

Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 19 hours 52 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 02/04/2026 at 17:45, 19 hours 52 minutes ago

January 2026

View all LES ECHOS COMFI WIRE